PT-141 10mg

Research Specifications

Sequence:
Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH
CAS:
189691-06-3
Molecular Weight:
1025.18 Da
Vial:
10mg lyophilized
Purity:
≥98% HPLC verified

PT-141 10mg

Bremelanotide cyclic heptapeptide

CAS: 189691-06-3

2019

FDA Vyleesi approval

AMAG Pharma

1.75 mg

Rx dose (Vyleesi)

Product label

~2 hr

Half-life

Clinical PK

Receptor Targets

MC4RPrimary target — central libido signaling
MC3RSecondary — satiety/autonomic modulation
MC1RWeak binding — minimal pigmentation effect
$62.99In Stock
Buy Now
≥98% Purity Verified Free Shipping $200+ HPLC Tested

Reconstitution & Dosing Guide

BAC Water

2mL

Final Concentration

5 mg/mL

Per Dose

1.75 mg = 0.35 mL (35 IU) · 1 mg = 0.2 mL (20 IU)

Administer 45 min–4 hours prior to intended effect window in research protocols

Published References

  1. 1.
    Kingsberg SA, Clayton AH, Portman D, et al.. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology (2019) PMID: 31599840
  2. 2.
    Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide. Journal of Urology (2008) PMID: 18423695

Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.

Price Comparison

SupplierPurityPriceShipping
our verified supplier>98% HPLC$62.99Free over $200
Generic Research SuppliersVaries (often <95%)Similar–HigherVaries
Pharmaceutical (Rx only)Pharmaceutical gradeNot available for researchRx required

PT-141 10mg

$62.99

Buy Now